The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers

Critical Reviews in Clinical Laboratory Sciences

Volumn 41, Issue 3, 2004, Pages 265-312

  Clements, Judith A ^a   Willemsen, Nicole M ^a   Myers, Stephen A ^a   Dong, Ying ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Central nervous system; Gene family; Hormone dependent cancers; KLK hK; Skin; Tissue specific expression

Indexed keywords

BIOLOGICAL MARKER; ENZYME PRECURSOR; HORMONE; ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TISSUE KALLIKREIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BIOCHEMISTRY; BLOOD CLOTTING; BREAST CARCINOMA; CENTRAL NERVOUS SYSTEM; CHROMOSOME 19Q; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; EXON; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE SEQUENCE; GENE STRUCTURE; GENETIC CODE; GENOME; GROWTH REGULATION; HEALTH STATUS; HORMONE ACTION; HUMAN; IN VITRO STUDY; MOUSE; MULTIGENE FAMILY; NERVE CELL PLASTICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PSORIASIS; RAT; REVIEW; RODENT; SEMINAL PLASMA; SEQUENCE HOMOLOGY; SKIN EXFOLIATION; TESTIS CARCINOMA; TOOTH DEVELOPMENT;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS, HORMONE-DEPENDENT; SEQUENCE HOMOLOGY, AMINO ACID; SERINE ENDOPEPTIDASES; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

RODENTIA;

EID: 3042750282     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360490471931     Document Type: Review

References (431)

1. Kraut H, Frey EK, Werle E. Der nachweis eines kreislauf-hormons in der pankreasdrüse. Hoppeseylers Z Physiol Chem 1930; 189: 97-106.
2. Werle E. Zur Kenntnis des haushalts des Kallikreins. Biochem Z 1934; 269: 415-34.
3. Fiedler F. Enzymology of glandular kallikreins. In Erdos EG, Ed. Handbook of Experimental Pharmacology Supplement, Bradykinin, Kallidin, and Kallikrein Pp. 103-61. New York: Springer-Verlag, 1979.
4. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15.
5. Asakai R, Davie EW, Chung DW. Organization of the gene for human factor XI. Biochemistry 1987; 26: 7221-8.
6. Evans BA, Yun ZX, Close JA, et al. Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry 1988; 27: 3124-9.
7. Clements JA. The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocr Rev 1989; 10: 393-419.
8. Clements JA. The molecular biology of the kallikreins and their roles in inflammation. In Farmer S, Ed. The Kinin system. Pp. 71-97. New York: Academic Press, 1997.
9. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
10. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001; 22: 184-204.
11. Berg T, Bradshaw RA, Carretero OA, et al. A common nomenclature for members of the tissue (glandular) kallikrein gene families. Agents Actions Suppl 1992; 38 (Pt 1): 19-25.
12. Diamandis EP, Yousef GM, Clements J, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000; 46: 1855-8.
13. Evans BA, Drinkwater CC, Richards RI. Mouse glandular kallikrein genes: Structure and partial sequence analysis of the kallikrein gene locus. J Biol Chem 1987; 262: 8027-34.
14. Olsson AY, Lundwall A. Organization and evolution of the glandular kallikrein locus in Mus musculus. Biochem Biophys Res Commun 2002; 299: 305-11.
15. Riegman PH, Vlietstra RJ, Suurmeijer L, et al. Characterization of the human kallikrein locus. Genomics 1992; 14: 6-11.
16. Southard-Smith M, Pierce JC, MacDonald RJ. Physical mapping of the rat tissue kallikrein family in two gene clusters by analysis of P1 bacteriophage clones. Genomics 1994; 22: 404-17.
17. Kurtz TW, St Lezin EM. Gene mapping in experimental hypertension. J Am Soc Nephrol 1992; 3: 28-34.
18. Gan L, Lee I, Smith R, et al. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 2000; 257: 119-30.
19. Harvey TJ, Hooper JD, Myers SA, et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275: 37397-406.
20. Yousef GM, Luo LY, Diamandis EP. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res 1999; 19: 2843-52.
21. Yousef GM, Chang A, Scorilas A, et al. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276: 125-33.
22. Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998; 35: 275-368.
23. Diamandis EP, Yousef GM, Luo LY, et al. The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 2000; 11: 54-60.
24. Clements J, Hooper J, Dong Y et al. The expanded human kallikrein (KLK) gene family: Genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001; 382: 5-14.
25. Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 2000; 59: 1-14.
26. Becker C, Noldus J, Diamandis E, et al. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001; 38: 357-99.
27. Diamandis EP, Yousef GM. Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev Mol Diagn 2001; 1: 182-90.
28. Diamandis EP, Yousef GM. Human tissue kallikreins: A family of new cancer biomarkers. Clin Chem 2002; 48: 1198-205.
29. Stephan C, Jung K, Diamandis EP, et al. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002; 59: 2-8.
30. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family - a novel panel of cancer biomarkers. Tumour Biol 2002; 23: 185-92.
31. Yousef GM, Diamandis EP. Kallikreins, steroid hormones and ovarian cancer: Is there a link? Minerva Endocrinol 2002; 27: 157-66.
32. Yousef GM, Diamandis EP. An overview of the kallikrein gene families in humans and other species: Emerging candidate tumour markers. Clin Biochem 2003; 36: 443-52.
33. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62: 27-33.
34. Luo LY, Yousef G, Diamandis EP. Human tissue kallikreins and testicular cancer. APMIS 2003; 111: 225-32.
35. Yousef GM, Diamandis EP. Tissue kallikreins: New players in normal and abnormal cell growth? Thromb Haemost 2003; 90: 7-16.
36. Yousef GM, Diamandis EP. Human tissue kallikreins: A new enzymatic cascade pathway? Biol Chem 2002; 383: 1045-57.
37. Simmer JP, Hu JC. Expression, structure, and function of enamel proteinases. Connect Tissue Res 2002; 43: 441-9.
38. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383-91.
39. Yousef GM, Kishi T, Diamandis EP. Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 2003; 329: 1-8.
40. Sharma JN. Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol 2003; 43: 1187-95.
41. Tomimatsu Y, Idemoto S, Moriguchi S, et al. Proteases involved in long-term potentiation. Life Sci 2002; 72: 355-61.
42. Bhoola K, Ramsaroop R, Plendl J, et al. Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 2001; 382: 77-89.
43. Foussias G, Yousef GM, Diamandis EP. Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). Genomics 2000; 67: 171-8.
44. Yousef GM, Diamandis M, Jung K, et al. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. Genomics 2001; 74: 385-95.
45. Baker AR, Shine J. Human kidney kallikrein: cDNA cloning and sequence analysis. DNA 1985; 4: 445-50.
46. Fukushima D, Kitamura N, Nakanishi S. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry 1985; 24: 8037-43.
47. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987; 6: 429-37.
48. Henttu P, Vihko P. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun 1989; 160: 903-10.
49. Richards RI, Holman K, Shen Y, et al. Human glandular kallikrein genes: Genetic and physical mapping of the KLK1 locus using a highly polymorphic microsatellite PCR marker. Genomics 1991; 11: 77-82.
50. Stephenson SA, Verity K, Ashworth LK, et al. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999; 274: 23210-4.
51. Dihanich M, Spiess M. A novel serine proteinase-like sequence from human brain. Biochim Biophys Acta 1994; 1218: 225-8.
52. Hansson L, Stromqvist M, Backman A, et al. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem 1994; 269: 19420-6.
53. Anisowicz A, Sotiropoulou G, Stenman G, et al. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996; 2: 624-36.
54. Liu XL, Wazer DE, Watanabe K, et al. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996; 56: 3371-9.
55. Little SP, Dixon EP, Norris F, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 1997; 272: 25135-42.
56. Yamashiro K, Tsuruoka N, Kodama S, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta 1997; 1350: 11-4.
57. Yoshida S, Taniguchi M, Hirata A, et al. Sequence analysis and expression of human neuropsin cDNA and gene. Gene 1998; 213: 9-16.
58. Yoshida S, Taniguchi M, Suemoto T, et al. cDNA cloning and expression of a novel serine protease, TLSP. Biochim Biophys Acta 1998; 1399: 225-8.
59. Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem 1999; 274: 30033-40.
60. Nelson PS, Gan L, Ferguson C, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999; 96: 3114-9.
61. Tanimoto H, Underwood LJ, Shigemasa K, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999; 86: 2074-82.
62. Underwood LJ, Tanimoto H, Wang Y, et al. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 1999; 59: 4435-9.
63. Hu JC, Zhang C, Sun X, et al. Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors. Gene 2000; 251: 1-8.
64. Yousef GM, Diamandis EP. The new kallikrein-like gene, KLK-L2: Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem 1999; 274: 37511-6.
65. Yousef GM, Scorilas A, Diamandis EP. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 2000; 63: 88-96.
66. Yousef GM, Diamandis EP. The expanded human kallikrein gene family: Locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics 2000; 65: 184-94.
67. Yousef GM, Luo LY, Scherer SW, et al. Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics 1999; 62: 251-9.
68. Yousef GM, Obiezu CV, Luo LY, et al. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999; 59: 4252-6.
69. Yousef GM, Chang A, Diamandis EP. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 2000; 275: 11891-8.
70. Yousef GM, Scorilas A, Jung K, et al. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 2001; 276: 53-61.
71. Yousef GM, Scorilas A, Magklara A, et al. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. Gene 2000; 254: 119-28.
72. Luo L, Herbrick JA, Scherer SW, et al. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. Biochem Biophys Res Commun 1998; 247: 580-6.
73. Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (proPSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001; 40: 1679-87.
74. Yousef GM, Magklara A, Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 2000; 69: 331-41.
75. Yousef GM, Magklara A, Chang A, et al. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 2001; 61: 3425-31.
76. Hooper JD, Bui LT, Rae FK, et al. Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 2001; 73: 117-22.
77. Howles PN, Dickinson DP, DiCaprio LL, et al. Use of a cDNA recombinant for the gamma-subunit of mouse nerve growth factor to localize members of this multigene family near the TAM-1 locus on chromosome 7. Nucleic Acids Res 1984; 12: 2791-805.
78. Wines DR, Brady JM, Southard EM, et al. Evolution of the rat kallikrein gene family: Gene conversion leads to functional diversity. J Mol Evol 1991; 32: 476-92.
79. Yamanaka H, He X, Matsumoto K, et al. Protease M/neurosin mRNA is expressed in mature oligodendrocytes. Brain Res Mol Brain Res 1999; 71: 217-24.
80. Chen ZL, Momota Y, Kato K, et al. Expression of neuropsin mRNA in the mouse embryo and the pregnant uterus. J Histochem Cytochem 1998; 46: 313-20.
81. Backman A, Stranden P, Brattsand M, et al. Molecular cloning and tissue expression of the murine analog to human stratum corneum chymotryptic enzyme. J Invest Dermatol 1999; 113: 152-5.
82. Mitsui S, Okui A, Kominami K, et al. cDNA cloning and tissue-specific splicing variants of mouse hippostasin/TLSP (PRSS20). Biochim Biophys Acta 2000; 1494: 206-10.
83. Wines DR, Brady JM, Pritchett DB, et al. Organization and expression of the rat kallikrein gene family. J Biol Chem 1989; 264: 7653-62.
84. Chapdelaine P, Gauthier E, Ho-Kim MA, et al. Characterization and expression of the prostatic arginine esterase gene, a canine glandular kallikrein. DNA Cell Biol 1991; 10: 4959.
85. Mitsui S, Yamada T, Okui A, et al. A novel isoform of a kallikrein-like protease, TLSP/hippostasin, (PRSS20), is expressed in the human brain and prostate. Biochem Biophys Res Commun 2000; 272: 205-11.
86. Dong Y, Kaushal A, Brattsand M, et al. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003; 9: 1710-20.
87. Nakamura T, Mitsui S, Okui A, et al. Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines. The Prostate 2001; 49: 72-8.
88. Korkmaz KS, Korkmaz CG, Pretlovv TG, et al. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: Intracellular localization, alternative cDNA forms, and regulation by multiple hormones. DNA Cell Biol 2001; 20: 435-45.
89. Riegman PH, Klaassen P, van der Korput JA, et al. Molecular cloning and characterization of novel prostate antigen cDNA's. Biochem Biophys Res Commun 1988; 155: 181-8.
90. Riegman PH, Vlietstra RJ, van der Korput HA, et al. Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 1991; 76: 181-90.
91. Chen LM, Murray SR, Chai KX, et al. Molecular cloning and characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Braz J Med Biol Res 1994; 27: 1829-38.
92. Rae F, Bulmer B, Nicol D, et al. The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology 1999; 45: 83-8.
93. Liu XF, Essand M, Vasmatzis G, et al. Identification of three new alternate human kallikrein 2 transcripts: Evidence of long transcript and alternative splicing. Biochem Biophys Res Commun 1999; 264: 833-9.
94. Tanaka T, Isono T, Yoshiki T, et al. A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Res 2000; 60: 56-9.
95. Obiezu CV, Diamandis EP. An alternatively spliced variant of KLK4 expressed in prostatic tissue. Clin Biochem 2000; 33: 599-600.
96. Heuze N, Olayat S, Gutman N, et al. Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Res 1999; 59: 2820-4.
97. Heuze-Vourc'h N, Leblond V, Olayat S, et al. Characterization of PSA-RP2, a protein related to prostate-specific antigen and encoded by alternative hKLK3 transcripts. Eur J Biochem 2001; 268: 4408-13.
98. Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (klk4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001; 7: 2363-71.
99. Myers SA, Clements JA. Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J Clin Endocrinol Metab 2001; 86: 2323-6.
100. Magklara A, Scorilas A, Katsaros D, et al. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001; 7: 806-11.
101. Chang A, Yousef GM, Jung K, et al. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: Differential expression in the human testis and testicular cancer. Anticancer Res 2001; 21: 3147-52.
102. David A, Mabjeesh N, Azar I, et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem 2002; 277: 18084-90.
103. Heuze-Vourc'h N, Leblond V, Courty Y. Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). Eur J Biochem 2003; 270: 706-14.
104. Mitsui S, Tsuruoka N, Yamashiro K, et al. A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain. Eur J Biochem 1999; 260: 627-34.
105. Nakamura T, Mitsui S, Okui A, et al. Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate. The Prostate 2003; 54: 299-305.
106. Ohta T, Basten CJ, Gene conversion generates hypervariability at the variable regions of kallikreins and their inhibitors. Mol Phylogenet Evol 1992; 1: 87-90.
107. Bridon DP, Dowell BL. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Urology 1995; 45: 801-6.
108. Gomis-Ruth FX, Bayes A, Sotiropoulou G, et al. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J Biol Chem 2002; 277: 27273-81.
109. Takada Y, Skidgel RA, Erdos EG. Purification of human urinary prokallikrein: Identification of the site of activation by the metalloproteinase thermolysin. Biochem J 1985; 232: 851-8.
110. Angermann A, Rahn HP, Hektor T, et al. Purification and characterization of human salivary-gland prokallikrein from recombinant baculovirus-infected insect cells. Eur J Biochem 1992; 206: 225-33.
111. Skytt A, Stromqvist M, Egelrud T. Primary substrate specificity of recombinant human stratum corneum chymotryptic enzyme. Biochem Biophys Res Commun 1995; 211: 586-9.
112. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate specific antigen: Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997; 272: 21582-8.
113. Lu HS, Hsu YR, Lu LI, et al. Isolation and characterization of human tissue kallikrein produced in Escherichia coli: Biochemical comparison to the enzymatically inactive prokallikrein and methionyl kallikrein. Protein Expr Purif 1996; 8: 215-26.
114. Lu HS, Hsu YR, Narhi LO, et al. Purification and characterization of human tissue prokallikrein and kallikrein isoforms expressed in Chinese hamster ovary cells. Protein Expr Purif 1996; 8: 227-37.
115. Lovgren J, Rajakoski K, Karp M, et al. Activation of the zymogen form of prostate specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997; 238: 549-55.
116. Kumar A, Mikolajczyk SD, Goel AS, et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997; 57: 3111-4.
117. Takayama TK, McMullen BA, Nelson PS, et al. Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001; 40: 15341-8.
118. Kumar A, Goel AS, Hill TM, et al. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 1996; 56: 5397-402.
119. Kumar A, Mikolajczyk SD, Hill TM, et al. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. The Prostate 2000; 44: 248-54.
120. Mikolajczyk SD, Millar LS, Marker KM, et al. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem 1997; 246: 440-6.
121. Lovgren J, Airas K, Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2): Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur J Biochem 1999; 262: 781-9.
122. Lovgren J, Tian S, Lundwall A, et al. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem 1999; 266: 1050-5.
123. Denmeade SR, Lovgren J, Khan SR, et al. Activation of latent protease function of prohK2, but not pro-PSA, involves autoprocessing. The Prostate 2001; 48: 122-6.
124. Magklara A, Mellati AA, Wasney GA, et al. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 2003; 307: 948-55.
125. Bernett MJ, Blaber SI, Scarisbrick IA, et al. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 2002; 277: 24562-70.
126. Sotiropoulou G, Rogakos V, Tsetsenis T, et al. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol Res 2003; 13: 381-91.
127. Hervio LS, Coombs GS, Bergstrom RC, et al. Negative selectivity and the evolution of protease cascades: The specificity of plasmin for peptide and protein substrates. Chem Biol 2000; 7: 443-53.
128. Mikolajczyk SD, Millar LS, Kumar A, et al. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. The Prostate 1998; 34: 44-50.
129. Kapadia C, Chang A, Sotiropoulou G, et al. Human kallikrein 13: Production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 2003; 49: 77-86.
130. Hsieh MC, Cooperman BS. The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA). Biochim Biophys Acta 2000; 1481: 75-87.
131. Bode W, Chen Z, Bartels K, et al. Refined 2 A x-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase: Crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. J Mol Biol 1983; 164: 237-82.
132. Katz BA, Liu B, Barnes M, et al. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein Sci 1998; 7: 875-85.
133. Bax B, Blundell TL, Murray-Rust J, et al. Structure of mouse 7S NGF: A complex of nerve growth factor with four binding proteins. Structure 1997; 5: 1275-85.
134. Timm DE, The crystal structure of the mouse glandular kallikrein-13 (prorenin converting enzyme). Protein Sci 1997; 6: 1418-25.
135. Kishi T, Kato M, Shimizu T, et al. Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis. J Biol Chem 1999; 274: 4220-4.
136. Carvalho AL, Dias JM, Sanz L, et al. Purification, crystallization and identification by x-ray analysis of a prostate kallikrein from horse seminal plasma. Acta Crystallogr D Biol Crystallogr 2001; 57: 1180-3.
137. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.
138. Frenette G, Deperthes D, Tremblay RR, et al. Purification of enzymatically active kallikrein hK2 from human seminal plasma. Biochim Biophys Acta 1997; 1334: 109-15.
139. Stephan C, Jung K, Schnorr D, et al. Re: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2002; 167: 259-60.
140. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-63.
141. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25.
142. Zhou GX, Chao L, Chao J. Kallistatin: A novel human tissue kallikrein inhibitor: Purification, characterization, and reactive center sequence. J Biol Chem 1992; 267: 25873-80.
143. Grauer LS, Finlay JA, Mikolajczyk SD, et al. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 1998; 19: 407-11.
144. Mikolajczyk SD, Millar LS, Kumar A, et al. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999; 81: 438-42.
145. Mikolajczyk SD, Millar LS, Marker KM, et al. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res 1999; 59: 3927-30.
146. Hutchinson S, Luo LY, Yousef GM, et al. Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. Clin Chem 2003; 49: 746-51.
147. Yousef GM, Kapadia C, Polymeris ME, et al. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochim Biophys Acta 2003; 1628: 88-96.
148. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
149. Miao RQ, Agata J, Chao L, et al. Kallistatin is anew inhibitor of angiogenesis and tumor growth. Blood 2002; 100: 3245-52.
150. Chao J, Miao RQ, Chen V, et al. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem 2001; 382: 15-21.
151. Roberts RA, Gullick WJ. Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J Cell Sci 1989; 94 (Pt 3): 527-35.
152. Maeda H, Wu J, Okamoto T, et al. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999; 43: 115-28.
153. Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28.
154. Wolf WC, Evans DM, Chao L, et al. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol 2001; 159: 1797-805.
155. Emanueli C, Zacheo A, Minasi A, et al. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 2000; 20: 2379-85.
156. Emanueli C, Minasi A, Zacheo A, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001; 103: 125-32.
157. Emanueli C, Salis MB, Stacca T, et al. Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 2001; 38: 136-41.
158. Miao RQ, Chen V, Chao L, et al. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 2003; 284: C1604-13.
159. Rehault S, Monget P, Mazerbourg S, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001; 268: 2960-8.
160. Tschesche H, Kohnert U, Fedrowitz J, et al. Tissue kallikrein effectively activates latent degrading metalloenzymes. Adv Exp Med Biol 1989; 247A: 545-8.
161. List K, Jensen ON, Bugge TH, et al. Plasminogen-independent initiation of the prourokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 2000; 39: 508-15.
162. Iwadate H, Sugisaki T, Kudo M, et al. Actions of insulin-like growth factor binding protein-5 (IGFBP-5) are potentially regulated by tissue kallikrein in rat brains. Life Sci 2003; 73: 3149-58.
163. Hecquet C, Tan F, Marcic BM, et al. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 2000; 58: 828-36.
164. Deddish PA, Hecquet C, Erdos EG, et al. B2R of bradykinin activated by proteases. Hypertension 2003; 42: e1-2.
165. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-82.
166. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899-903.
167. Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen: Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989; 264: 1894-900.
168. Deperthes D, Frenette G, Brillard-Bourdet M, et al. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996; 17: 659-65.
169. Espana F, Gilabert J, Estelles A, et al. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991; 64: 309-20.
170. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994; 220: 45-53.
171. Malm J, Hellman J, Hogg P, et al. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. The Prostate 2000; 45: 132-9.
172. Obiezu CV, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002; 48: 1232-40.
173. Diamandis EP, Yousef GM, Soosaipillai AR, et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000; 33: 369-75.
174. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 2003; 49: 87-96.
175. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: A new biomarker of prostate and ovarian carcinoma. Cancer Res 2002; 62: 295-300.
176. Luo LY, Grass L, Howarth DJ, et al. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 2001; 47: 237-46.
177. Brillard-Bourdet M, Rehault S, Juliano L, et al. Amidolytic activity of prostatic acid phosphatase on human semenogelins and semenogelin-derived synthetic substrates. Eur J Biochem 2002; 269: 390-5.
178. Cohen P, Graves HC, Peehl DM, et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046-53.
179. Fielder PJ, Rosenfeld RG, Graves HC, et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul 1994; 4: 164-72.
180. Koistinen H, Paju A, Koistinen R, et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. The Prostate 2002; 50: 112-8.
181. Sutkowski DM, Goode RL, Baniel J, et al. Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1663-9.
182. Killian CS, Corral DA, Kawinski E, et al. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192: 940-7.
183. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998; 44: 705-23.
184. Yonou H, Aoyagi Y, Kanomata N, et al. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 2001; 289: 1082-7.
185. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526-31.
186. Iwamura M, Hellman J, Cockett AT, et al. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996; 48: 317-25.
187. Fortier AH, Nelson BJ, Grella DK, et al. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635-40.
188. Fortier AH, Holaday JW, Liang H, et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. The Prostate 2003; 56: 212-9.
189. Heidtmann HH, Nettelbeck DM, Mingels A, et al. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999; 81: 1269-73.
190. Charlesworth MC, Young CY, Miller VM, et al. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl 1999; 20: 220-9.
191. Deperthes D, Marceau F, Frenette G, et al. Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Biochim Biophys Acta 1997; 1343: 102-6.
192. Colman RW, Jameson BA, Lin Y, et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-50.
193. Colman RW. Role of the light chain of high molecular weight kininogen in adhesion, cell-associated proteolysis and angiogenesis. Biol Chem 2001; 382: 65-70.
194. Balbay MD, Juang P, Llansa N, et al. Stable transfection of human prostate cancer cell line PC-3 with prostate-specific antigen induces apoptosis both in vivo and in vitro. Proc Am Assoc Cancer Res (Abstract) 1999; 40: 225-6.
195. Denmeade SR, Litvinov I, Sokoll LJ, et al. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate 2003; 56: 45-53.
196. Lai LC, Erbas H, Lennard TW, et al. Prostate-specific antigen in breast cyst fluid: Possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 1996; 66: 743-6.
197. Kennedy-Smith AG, McKenzie JL, Owen MC, et al. Prostate specific antigen inhibits immune responses in vitro: A potential role in prostate cancer. J Urol 2002; 168: 741-7.
198. Aalamian M, Tourkova IL, Chatta GS, et al. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 2003; 170: 2026-30.
199. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003; 30: 649-58.
200. Horig H, Lee CS, Kaufman HL. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2002; 2: 395-408.
201. Wolchok JD, Gregor PD, Nordquist LT, et al. DNA vaccines: An active immunization strategy for prostate cancer. Semin Oncol 2003; 30: 659-66.
202. Xiao-Ya S, Donald S, Phang JM. Prostate-specific antigen (PSA) stimulates generation of reactive oxygen species (ROS) in LNCaP cells by a nonproteolytic mechanism. Proc Am Assoc Cancer Res (Abstract) 2000; 41: 43.
203. Sun XY, Donald SP, Phang JM. Testosterone and prostate-specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 2001; 22: 1775-80.
204. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002; 84: 131-41.
205. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089-94.
206. Frenette G, Tremblay RR, Lazure C, et al. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 1997; 71: 897-9.
207. Simmer JP, Fukae M, Tanabe T, et al. Purification, characterization, and cloning of enamel matrix serine proteinase 1. J Dent Res 1998; 77: 377-86.
208. Scully JL, Bartlett JD, Chaparian MG, et al. Enamel matrix serine proteinase 1: Stage-specific expression and molecular modeling. Connect Tissue Res 1998; 39: 111-22; discussion 41-9.
209. Bartlett JD, Simmer JP, Ryu OH, et al. Proteinases in developing dental enamel: Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. Crit Rev Oral Biol Med 1999; 10: 425-41.
210. Hu JC, Ryu OH, Chen JJ, et al. Localization of EMSP1 expression during tooth formation and cloning of mouse cDNA. J Dent Res 2000; 79: 70-6.
211. Ryu O, Hu JC, Yamakoshi Y, et al. Porcine kallikrein-4 activation, glycosylation, activity, and expression in prokaryotic and eukaryotic hosts. Eur J Oral Sci 2002; 110: 358-65.
212. Hu JC, Sun X, Zhang C, et al. Enamelysin and kallikrein-4 mRNA expression in developing mouse molars. Eur J Oral Sci 2002; 110: 307-15.
213. D'Souza RN, Aberg T, Gaikwad J, et al. Cbfa1 is required for epithelial-mesenchymal interactions regulating tooth development in mice. Development 1999; 126: 2911-20.
214. Scarisbrick IA, Towner MD, Isackson PJ. Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 1997; 17: 8156-68.
215. Scarisbrick IA, Asakura K, Blaber S, et al. Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter. Glia 2000; 30: 219-30.
216. Scarisbrick IA, Isackson PJ, Ciric B, et al. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol 2001; 431: 347-61.
217. Scarisbrick IA, Blaber SI, Lucchinetti CF, et al. Activity of a newly identified serine protease in CNS demyelination. Brain 2002; 125: 1283-96.
218. Blaber SI, Scarisbrick IA, Bernett MJ, et al. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 2002; 41: 1165-73.
219. Ogawa K, Yamada T, Tsujioka Y, et al. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 2000; 54: 419-26.
220. Iwata A, Maruyama M, Akagi T, et al. Alpha-synuclein degradation by serine protease neurosin: Implication for pathogenesis of synucleinopathies. Hum Mol Genet 2003; 12: 2625-35.
221. Okui A, Kominami K, Uemura H, et al. Characterization of a brain-related serine protease, neurosin (human kallikrein 6), in human cerebrospinal fluid. Neuroreport 2001; 12: 1345-50.
222. Chen ZL, Yoshida S, Kato K, et al. Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci 1995; 15: 5088-97.
223. Shimizu C, Yoshida S, Shibata M, et al. Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J Biol Chem 1998; 273: 11189-96.
224. Yoshida S, Shiosaka S. Plasticity-related serine proteases in the brain (review). Int J Mol Med 1999; 3: 405-9.
225. Komai S, Matsuyama T, Matsumoto K, et al. Neuropsin regulates an early phase of schaffer-collateral long-term potentiation in the murine hippocampus. Eur J Neurosci 2000; 12: 1479-86.
226. Hirata A, Yoshida S, Inoue N, et al. Abnormalities of synapses and neurons in the hippocampus of neuropsin-deficient mice. Mol Cell Neurosci 2001; 17: 600-10.
227. Tani N, Matsumoto K, Ota I, et al. Effects of fibronectin cleaved by neuropsin on cell adhesion and migration. Neurosci Res 2001; 39: 247-51.
228. Matsumoto-Miyai K, Ninomiya A, Yamasaki H, et al. NMDA-dependent proteolysis of presynaptic adhesion molecule L1 in the hippocampus by neuropsin. J Neurosci 2003; 23: 7727-36.
229. He XP, Shiosaka S, Yoshida S. Expression of neuropsin in oligodendrocytes after injury to the CNS. Neurosci Res 2001; 39: 455-62.
230. Akita H, Matsuyama T, Iso H, et al. Effects of oxidative stress on the expression of limbic-specific protease neuropsin and avoidance learning in mice. Brain Res 1997; 769: 86-96.
231. Hoffman KB, Martinez J, Lynch G. Proteolysis of cell adhesion molecules by serine proteases: A role in long term potentiation? Brain Res 1998; 811: 29-33.
232. Egelrud T, Lundstrom A. A chymotrypsin-like proteinase that may be involved in desquamation in plantar stratum corneum. Arch Dermatol Res 1991; 283: 108-12.
233. Cui CY, Takahashi M, Tezuka T. 30-kDa trypsin-like proteases in the plantar stratum corneum. J Dermatol 1997; 24: 504-9.
234. Ekholm E, Egelrud T. The expression of stratum corneum chymotryptic enzyme in human anagen hair follicles: Further evidence for its involvement in desquamation-like processes. Br J Dermatol 1998; 139: 585-90.
235. Horikoshi T, Igarashi S, Uchiwa H, et al. Role of endogenous cathepsin D-like and chymotrypsin-like proteolysis in human epidermal desquamation. Br J Dermatol 1999; 141: 453-9.
236. Ekholm E, Egelrud T. Expression of stratum corneum chymotryptic enzyme in relation to other markers of epidermal differentiation in a skin explant model. Exp Dermatol 2000; 9: 65-70.
237. Simon M, Jonca N, Guerrin M, et al. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 2001; 276: 20292-9.
238. Sondell B, Thornell LE, Egelrud T. Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. J Invest Dermatol 1995; 104: 819-23.
239. Inoue N, Kuwae K, Ishida-Yamamoto A, et al. Expression of neuropsin in the keratinizing epithelial tissue-immunohistochemical analysis of wild-type and nude mice. J Invest Dermatol 1998; 110: 923-31.
240. Kitayoshi H, Inoue N, Kuwae K, et al. Effect of 12-O-tetradecanoyl- phorbol ester and incisional wounding on neuropsin mRNA and its protein expression in murine skin. Arch Dermatol Res 1999; 291: 333-8.
241. Kuwae K, Matsumoto-Miyai K, Yoshida S, et al. Epidermal expression of serine protease, neuropsin (KLK8) in normal and pathological skin samples. Mol Pathol 2002; 55: 235-41.
242. Kirihara T, Matsumoto-Miyai K, Nakamura Y, et al. Prolonged recovery of ultraviolet B-irradiated skin in neuropsin (KLK8)-deficient mice. Br J Dermatol 2003; 149: 700-6.
243. Egelrud T. Stratum corneum chymotryptic enzyme. In Barrett AJ, Rawlings NP, Woessner JF, eds. Handbook of Proteolytic Enzymes. Pp. 87-89. London: Academic, 1998.
244. Nylander-Lundqvist E, Egelrud T. Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm Venereol 1997; 77: 203-6.
245. Brattsand M, Egelrud T. Purification and characterization of interleukin 1 beta from human plantar stratum corneum: Evidence of interleukin 1 beta processing in vivo not involving interleukin 1 beta convertase. Cytokine 1998; 10: 506-13.
246. Hansson L, Backman A, Ny A, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A model for chronic itchy dermatitis. J Invest Dermatol 2002; 118: 444-9.
247. Wong GW, Yang Y, Yasuda S, et al. Mouse mast cells express the tryptic protease neuropsin/Prss19. Biochem Biophys Res Commun 2003; 303: 320-5.
248. Chapdelaine P, Paradis G, Tremblay RR, et al. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988; 236: 205-8.
249. Swift GH, Craik CS, Stary SJ, et al. Structure of the two related elastase genes expressed in the rat pancreas. J Biol Chem 1984; 259: 14271-8.
250. Boulet AM, Erwin CR, Rutter WJ. Cell-specific enhancers in the rat exocrine pancreas. Proc Natl Acad Sci USA 1986; 83: 3599-603.
251. Wolf DA, Schulz P, Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol 1992; 6: 753-62.
252. Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: Characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 1993; 32: 6459-64.
253. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, et al. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997; 11: 1256-65.
254. Sun Z, Pan J, Balk SP. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate- specific antigen and kallikrein 2 genes. Nucleic Acids Res 1997; 25: 3318-25.
255. Komatsu N, Takata M, Otsuki N, et al. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003; 121: 542-9.
256. MacDonald RJ, Southard-Smith EM, Kroon E. Disparate tissue-specific expression of members of the tissue kallikrein multigene family of the rat. J Biol Chem 1996; 271: 13684-90.
257. Penschow JD, Coghlan JP. Secretion of glandular kallikrein and renin from the basolateral pole of mouse submandibular duct cells: An immunocytochemical study. J Histochem Cytochem 1993; 41: 95-103.
258. Schachter M, Peret MW, Moriwaki C, et al. Localization of kallikrein in submandibular gland of cat, guinea pig, dog, and man by the immunoperoxidase method. J Histochem Cytochem 1980; 28: 1295-300.
259. Henttu P, Vihko P. Prostate-specific antigen and human glandular kallikrein: Two kallikreins of the human prostate. Ann Med 1994; 26: 157-64.
260. Petraki CD, Karavana VN, Skoufogiannis PT, et al. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001; 49: 1431-41.
261. Petraki CD, Karavana VN, Revelos KJ, et al. Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. Histochem J 2002; 34: 313-22.
262. Petraki CD, Karavana VN, Luo LY, et al. Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem 2002; 50: 1247-61.
263. Petraki CD, Gregorakis AK, Papanastasiou PA, et al. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis 2003; 6: 223-7.
264. Harvey TJ, Dong Y, Bui L, et al. Production and characterization of anti-peptide kallikrein 4 antibodies: Use of computer modelling to design peptides specific to kallikrein 4. In Russell PJ, Jackson P, Kingsley EA, eds. Prostate Cancers: Methods and Protocols. Pp. 241-54. New Jersey: The Humana Press, 2003.
265. Cumming AD, Walsh T, Wojtacha D, et al. Expression of tissue kallikrein in human kidney. Clin Sci (Lond) 1994; 87: 5-11.
266. Sondell B, Thornell LE, Stigbrand T, et al. Immunolocalization of stratum corneum chymotryptic enzyme in human skin and oral epithelium with monoclonal antibodies: Evidence of a proteinase specifically expressed in keratinizing squamous epithelia. J Hisiochem Cytochem 1994; 42: 459-65.
267. Ekholm E, Sondell B, Stranden P, et al. Expression of stratum corneum chymotryptic enzyme in human sebaceous follicles. Acta Derm Venereol 1998; 78: 343-7.
268. Ekholm IE, Brattsand M, Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: A missing link in the desquamation process? J Invest Dermatol 2000; 114: 56-63.
269. Figueroa CD, MacIver AG, Mackenzie JC, et al. Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 1988; 89: 437-42,
270. Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997; 49: 857-62.
271. Vio CP, Figueroa CD, Caorsi I. Anatomical relationship between kallikrein-containing tubules and the juxtaglomerular apparatus in the human kidney. Am J Hypertens 1988; 1: 269-71.
272. Borgono CA, Grass L, Soosaipillai A, et al. Human kallikrein 14: A new potential biomarker for ovarian and breast cancer. Cancer Res 2003; 63: 9032-41.
273. Orstavik TB, Brandtzaeg P, Nustad K, et al. Immunohistochemical localization of kallikrein in human pancreas and salivary glands. J Histochem Cytochem 1980; 28: 557-62.
274. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, et al. Detection of prostate specific antigen in pancreas and salivary glands: A potential impact on prostate cancer overestimation. J Urol 1996; 156: 464-8.
275. Ishikawa T, Kashiwagi H, Iwakami Y, et al. Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase- polymerase chain reaction. Jpn J Clin Oncol 1998; 28: 723-8.
276. Yousef GM, Polymeris ME, Grass L, et al. Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003; 63: 3958-65.
277. Mahabeer R, Bhoola KD. Kallikrein and kinin receptor genes. Pharmacol Ther 2000; 88: 77-89.
278. Sawant S, Snyman C, Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol 2001; 1: 2063-80.
279. Meneton P, Bloch-Faure M, Hagege AA, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 2001; 98: 2634-9.
280. Pinto YM, Bader M, Pesquero JB, et al. Increased kallikrein expression protects against cardiac ischemia. FASEB J 2000; 14: 1861-3.
281. Silva JA, Jr., Araujo RC, Baltatu O, et al. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 2000; 14: 1858-60.
282. Devani M, Cugno M, Vecchi M, et al. Kallikrein-kinin system activation in Crohn's disease: Differences in intestinal and systemic markers. Am J Gastroenterol 2002; 97: 2026-32.
283. Margolius HS. Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 1998; 16: 337-49.
284. Ueno A, Oh-ishi S. Roles for the kallikrein-kinin system in inflammatory exudation and pain: Lessons from studies on kininogen-deficient rats. J Pharmacol Sci 2003; 93: 1-20.
285. Skidgel RA, Alhenc-Gelas F, Campbell WB. Prologue: Kinins and related systems: New life for old discoveries. Am J Physiol Heart Circ Physiol 2003; 284: 1886-91.
286. Cassim B, Mody G, Bhoola K. Kallikrein cascade and cytokines in inflamed joints. Pharmacol Ther 2002; 94: 1-34.
287. Wagner S, Kalb P, Lukosava M, et al. Activation of the tissue kallikrein-kinin system in stroke. J Neurol Sci 2002; 202: 75-6.
288. Raidoo DM, Bhoola KD. Pathophysiology of the kallikrein-kinin system in mammalian nervous tissue. Pharmacol Ther 1998; 79: 105-27.
289. Bernstein HG. Tissue kallikrein-like immunoreactive material decorates neuritic plaques of Alzheimer patients. Clin Neuropathol 1997; 16: 69-71.
290. Naicker S, Naidoo S, Ramsaroop R, et al. Tissue kallikrein and kinins in renal disease. Immunopharmacology 1999; 44: 183-92.
291. Dellalibera-Joviliano R, Reis ML, Donadi EA. Kinin system in lupus nephritis. Int Immunopharmacol 2001; 1: 1889-96.
292. Stadnicki A, Mazurek U, Plewka D, et al. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int Immunopharmacol 2003; 3: 939-44.
293. Briseid K, Johannesen S. Kallikrein modification with affinity to IgG present in higher amounts than normal in plasma from patients with Crohn's disease. Scand J Clin Lab Invest 2003; 63: 425-9.
294. Jaffa AA, Chai KX, Chao J, et al. Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 1992; 41: 789-95.
295. Raidoo DM, Ramsaroop R, Naidoo S, et al. Regional distribution of tissue kallikrein in the human brain. Immunopharmacology 1996; 32: 39-47.
296. Agostoni A, Cugno M. The kinin system: Biological mechanisms and clinical implications. Recenti Prog Med 2001; 92: 764-73.
297. Dlamini Z, Raidoo D, Bhoola K. Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. Immunopharmacology 1999; 43: 303-10.
298. Shiosaka S, Yoshida S. Synaptic microenvironments - structural plasticity, adhesion molecules, proteases and their inhibitors. Neurosci Res 2000; 37: 85-9.
299. Diamandis EP, Yousef GM, Petraki C, et al. Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin Biochem 2000; 33: 663-7.
300. Momota Y, Yoshida S, Ito J, et al. Blockade of neuropsin, a serine protease, ameliorates kindling epilepsy. Eur J Neurosci 1998; 10: 760-4.
301. Okabe A, Momota Y, Yoshida S, et al. Kindling induces neuropsin mRNA in the mouse brain. Brain Res 1996; 728: 116-20.
302. Davies B, Kearns IR, Ure J, et al. Loss of hippocampal serine protease BSP1/neuropsin predisposes to global seizure activity. J Neurosci 2001; 21: 6993-7000.
303. Tomizawa K, He X, Yamanaka H, et al. Injury induces neuropsin mRNA in the central nervous system. Brain Res 1999; 824: 308-11.
304. Shimizu-Okabe C, Yousef GM, Diamandis EP, et al. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. Neuroreport 2001; 12: 2747-51.
305. Mitsui S, Okui A, Uemura H, et al. Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. Ann N Y Acad Sci 2002; 977: 216-23.
306. Zarghooni M, Soosaipillai A, Grass L, et al. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin Biochem 2002; 35: 225-31.
307. Diamandis E, Scorilas A, Kishi T, et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clin Biochem 2004; 37: 230-7.
308. Melegos DN, Freedman MS, Diamandis EP. Prostate-specific antigen in cerebrospinal fluid. Clin Chem 1997; 43: 855.
309. Mannello F, Luchetti F, Falcieri E, et al. Prostate-specific antigen expression in neuroblastoma cell lines. Clin Chem 1998; 44: 1362-3.
310. Johnson B, Horn T, Sander C, et al. Expression of stratum corneum chymotryptic enzyme in ichthyoses and squamoproliferative processes. J Cutan Pathol 2003; 30: 358-62.
311. Sondell B, Dyberg P, Anneroth GK, et al. Association between expression of stratum corneum chymotryptic enzyme and pathological keratinization in human oral mucosa. Acta Derm Venereol 1996; 76: 177-81.
312. Ekholm E, Egelrud T. Stratum corneum chymotryptic enzyme in psoriasis. Arch Dermatol Res 1999; 291: 195-200.
313. Franzke CW, Baici A, Bartels J, et al. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J Biol Chem 1996; 271: 21886-90.
314. Vicanova J, Boyce ST, Harriger MD, et al. Stratum corneum lipid composition and structure in cultured skin substitutes is restored to normal after grafting onto athymic mice. J Investig Dermatol Symp Proc 1998; 3: 114-20.
315. Ny A, Egelrud T. Transgenic mice over-expressing a serine protease in the skin: Evidence of interferon gamma-independent MHC II expression by epidermal keratinocytes. Acta Derm Venereol 2003; 83: 322-7.
316. Young CY, Montgomery BT, Andrews PE, et al. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991; 51: 3748-52.
317. Henttu P, Liao SS, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992; 130: 766-72.
318. Young CY, Andrews PE, Montgomery BT, et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992; 31: 818-24.
319. Luke MC, Coffey DS. Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 1994; 15: 41-51.
320. Cleutjens KB, van Eekelen CC, van der Korput HA, et al. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996; 271: 6379-88.
321. Schuur ER, Henderson GA, Kmetec LA, et al. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271: 7043-51.
322. Zhang S, Murtha PE, Young CY. Defining a functional androgen responsive element in the 5′ far upstream flanking region of the prostate-specific antigen gene. Biochem Biophys Res Commun 1997; 231: 784-8.
323. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-504.
324. Mitchell SH, Murtha PE, Zhang S, et al. An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 2000; 168: 89-99.
325. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9: 601-10.
326. Cleutjens KB, van der Korput HA, van Eekelen CC, et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997; 11: 148-61.
327. Huang W, Shostak Y, Tarr P, et al. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 1999; 274: 25756-68.
328. Clements JA, Fuller P. Tissue kallikrein in the pituitary and brain. Front Neuroendocrinol 1990; 11: 38-51.
329. Clements JA, Mukhtar A, Verity K, et al. Kallikrein gene expression in human pituitary tissues. Clin Endocrinol (Oxf) 1996; 44: 223-31.
330. Fuller PJ, Matheson BA, MacDonald RJ, et al. Kallikrein gene expression in estrogen-induced pituitary tumors. Mol Cell Endocrinol 1988; 60: 225-32.
331. Powers CA. Elevated glandular kallikrein in estrogen-induced pituitary tumors. Endocrinology 1987; 120: 429-31.
332. Corthorn J, Valdes G. Variations in uterine kallikrein during cycle and early pregnancy in the rat. Biol Reprod 1994; 50: 1261-4.
333. Valdes G, Figueroa CD, Corthorn J. Temporospatial changes of kallikrein-like enzymes during the estrous cycle and pregnancy in the rat uterus. Biol Reprod 1996; 55: 236-45.
334. Corthorn J, Figueroa C, Valdes G. Estrogen and luminal stimulation of rat uterine kallikrein. Biol Reprod 1997; 56: 1432-8.
335. Clements J, Mukhtar A, Ehrlich A, et al. Glandular kallikrein gene expression in the human uterus. Braz J Med Biol Res 1994; 27: 1855-63.
336. Murray SR, Chao J, Lin FK, et al. Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol 1990: 15: S7-16.
337. Luo LY, Grass L, Diamandis EP. The normal epithelial cell-specific 1 (NES 1) gene is upregulated by steroid hormones in the breast carcinoma cell line BT-474. Anticancer Res 2000; 20: 981-6.
338. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306.
339. Partin AW, Hanks GE, Klein EA, et al. Prostate-specific antigen as a marker of disease activity in prostate cancer. Part 1. Oncology (Huntingt) 2002; 16: 1024-38.
340. Partin AW, Hanks GE, Klein EA, et al. Prostate-specific antigen as a marker of disease activity in prostate cancer, Part 2. Oncology (Huntingt) 2002; 16: 1218-24.
341. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95: 990-1000.
342. Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003; 52: 497-505.
343. Park HS, Cheon J, Cho HY, et al. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. Gene Ther 2003; 10: 1129-34.
344. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
345. Aleman M, Karakiewicz PI, Kupelian P, et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: Implications for screening. Urology 2003; 62: 70-4.
346. Lein M, Kwiatkowski M, Semjonow A, et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003; 170: 1175-9.
347. Kurek R, Ylikoski A, Renneberg H, et al. Quantitative PSA RT-PCR for preoperative staging of prostate cancer. The Prostate 2003; 56: 263-9.
348. Tanaka M, Murakami S, Suzuki N, et al. Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. Int J Urol 2000; 7: 83-7.
349. Hilz H, Noldus J, Hammerer P, et al. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol 1999; 36: 286-92.
350. Mikolajczyk SD, Millar LS, Wang TJ, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000; 60: 756-9.
351. Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001; 61: 6958-63.
352. Herrala A, Kurkela R, Vihinen M, et al. Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur J Biochem 1998; 255: 329-35.
353. Mikolajczyk SD, Millar LS, Wang TJ, et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 41-5.
354. Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of pro-prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003; 170: 723-6.
355. Chan TY, Mikolajczyk SD, Lecksell K, et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003; 62: 177-81.
356. Mikolajczyk SD, Marks LS, Partin AW, et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802.
357. Meng FJ, Shan A, Jin L, et al. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev 2002; 11: 305-9.
358. Henttu P, Lukkarinen O, Vihko P. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990; 45: 654-60.
359. Klee GG, Goodmanson MK, Jacobsen SJ, et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 1999; 45: 800-6.
360. Kwiatkowski MK, Recker F, Piironen T, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998; 52: 360-5.
361. Recker F, Kwiatkowski MK, Piironen T, et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 1998; 83: 2540-7.
362. Partin AW, Catalona WJ, Finlay JA, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology 1999; 54: 839-45.
363. Becker C, Piironen T, Pettersson K, et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology 2000; 55: 694-9.
364. Nam RK, Diamandis EP, Toi A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000; 18: 1036-42.
365. Becker C, Piironen T, Pettersson K, et al. Testing in serum for human
366. Scorilas A, Plebani M, Mazza S, et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. The Prostate 2003; 54: 220-9.
367. Haese A, Becker C, Noldus J, et al. Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 2000; 163: 1491-7.
368. Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. The Prostate 2001; 49: 101-9.
369. Haese A, Graefen M, Becker C, et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. The Prostate 2003; 54: 181-6.
370. Saedi MS, Hill TM, Kuus-Reichel K, et al. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 1998; 44: 2115-9.
371. Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 939-44.
372. Herrala AM, Porvari KS, Kyllonen AP, et al. Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 2001; 92: 2975-84.
373. Slawin KM, Shariat SF, Nguyen C, et al. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res 2000; 60: 7142-8.
374. Shariat SF, Kattan MW, Erdamar S, et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol 2003; 21: 1223-31.
375. Shariat SF, Roudier MP, Wilcox GE, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 2003; 63: 4662-70.
376. Day CH, Fanger GR, Retter MW, et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene 2002; 21: 7114-20.
377. Goyal J, Smith KM, Cowan JM, et al. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998; 58: 4782-6.
378. Yousef GM, Scorilas A, Chang A, et al. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. The Prostate 2002; 51: 126-32.
379. Yousef GM, Stephan C, Scorilas A, et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. The Prostate 2003; 56: 287-92.
380. Nakamura T, Stephan C, Scorilas A, et al. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology 2003; 61: 1042-6.
381. Stephan C, Yousef GM, Scorilas A, et al. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 2003; 169: 361-4.
382. Nakamura T, Scorilas A, Stephan C, et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003; 63: 6543-6.
383. Yu H, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 1993; 39: 2108-14.
384. Yu H, Diamandis EP. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995; 153: 1004-8.
385. Ferguson RA, Yu H, Kalyvas M, et al. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: Potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675-84.
386. Diamandis EP. Prostate specific antigen - new applications in breast and other cancers. Anti-cancer Res 1996; 16: 3983-4.
387. Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40: 171-8.
388. Yu H, Levesque MA, Clark GM, et al. Prognostic value of prostate-specific antigen for women with breast cancer. A large United States cohort study. Clin Cancer Res 1998; 4: 1489-97.
389. Borchert GH, Melegos DN, Tomlinson G, et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997; 76: 1087-94.
390. Yu H, Giai M, Diamandis EP, et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55: 2104-10.
391. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995; 41: 54-8.
392. Diamandis EP, Yu H, Sutherland DJ. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994; 32: 301-10.
393. Howarth DJ, Aronson IB, Diamandis EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer 1997; 75: 1646-51.
394. Sauter ER, Daly M, Linahan K, et al. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 967-70.
395. Mannello F, Gazzanelli G. Prostate-specific antigen (PSA/hK3): A further player in the field of breast cancer diagnostics? Breast Cancer Res 2001; 3: 238-43.
396. Magklara A, Scorilas A, Lopez-Otin C, et al. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. Clin Chem 1999; 45: 1774-80.
397. Black MH, Magklara A, Obiezu C, et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br J Cancer 2000; 82: 361-7.
398. Yousef GM, Scorilas A, Kyriakopoulou LG, et al. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clin Chem 2002; 48: 1241-50.
399. Luo LY, Diamandis EP, Look MP, et al. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer 2002; 86: 1790-6.
400. Dhar S, Bhargava R, Yunes M, et al. Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res 2001; 7: 3393-8.
401. Chang A, Yousef GM, Scorilas A, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002; 86: 1457-64.
402. Yousef GM, Borgono CA, Scorilas A, et al. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer 2002; 87: 1287-93.
403. Yousef GM, Scorilas A, Nakamura T, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat 2003; 78: 149-58.
404. Yousef GM, Yacoub GM, Polymeris ME, et al. Kallikrein gene downregulation in breast cancer. Br J Cancer 2004; 90: 167-72.
405. Yousef GM, Scorilas A, Magklara A, et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer 2002; 87: 1294-300.
406. Obiezu CV, Scorilas A, Katsaros D, et al. Higher human kallikrein gene 4 (klk4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001; 7: 2380-6.
407. Kim H, Scorilas A, Katsaros D, et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001; 84: 643-50.
408. Tanimoto H, Underwood LJ, Shigemasa K, et al. Increased expression of protease M in ovarian tumors. Tumour Biol 2001; 22: 11-8.
409. Diamandis EP, Yousef GM, Soosaipillai AR, et al. Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 2000; 33: 579-83.
410. Kyriakopoulou LG, Yousef GM, Scorilas A, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem 2003; 36: 135-43.
411. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003; 63: 2771-4.
412. Yousef GM, Kyriakopoulou LG, Scorilas A, et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res 2001; 61: 7811-8.
413. Luo LY, Katsaros D, Scorilas A, et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001; 7: 2372-9.
414. Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003; 90: 44-50.
415. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003; 63: 2223-7.
416. Yousef GM, Scorilas A, Katsaros D, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 2003; 21: 3119-26.
417. Yousef GM, Fracchioli S, Scorilas A, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 2003; 119: 346-55.
418. Borgono CA, Fracchioli S, Yousef GM, et al. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer 2003; 106: 605-10.
419. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994; 78: 1536-9.
420. Valdes G, Germain AM, Corthorn J, et al. Tissue kallikrein and bradykinin B2 receptor in human uterus in luteal phase and in early and late gestation. Endocrine 2001; 16: 207-15.
421. Matsumoto-Miyai K, Kitagawa R, Ninomiya A, et al. Decidualization induces the expression and activation of an extracellular protease neuropsin in mouse uterus. Biol Reprod 2002; 67: 1414-8.
422. Katsu Y, Takasu E, Iguchi T. Estrogen-independent expression of neuropsin, a serine protease in the vagina of mice exposed neonatally to diethylstilbestrol. Mol Cell Endocrinol 2002; 195: 99-107.
423. Yousef GM, Obiezu CV, Jung K, et al. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002; 60: 714-8.
424. Luo LY, Rajpert-De Meyts ER, Jung K, et al. Expression of the normal epithelial cellspecific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001; 85: 220-4.
425. Young CL, Barker WC, Tomaselli CM, et al. Serine proteases. In Dayhoff MO, Ed. Atlas of Protein Sequence and Structure, National Biomedical Research Foundation. Pp. 73-81. Maryland: Silver Springs, 1978.
426. Obiezu CV, Scorilas A, Magklara A, et al. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1558-61.
427. Malatesta M, Mannello F, Sebastiani M, et al. Differential distribution of soluble and complexed forms of prostate-specific antigen in cyst fluids of women with gross cystic breast disease. J Clin Lab Anal 2001; 15: 81-6.
428. Wald NJ, Hackshavv AK, Diamandis EP, et al. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. International Prenatal Screening Research Group. Prenat Diagn 1999; 19: 674-6.
429. Li B, Goyal J, Dhar S, et al. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res 2001; 61: 8014-21.
430. Yunes MJ, Neuschatz AC, Bornstein LE, et al. Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. Int J Radiat Oncol Biol Phys 2003; 56: 653-7.
431. Scorilas A, Borgono CA, Harbeck N, et al. Human kallikrein 13 protein in ovarian cancer cytosols: A new favorable prognostic marker. J Clin Oncol 2004; 22: 678-85.